Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emisphere reports encouraging data from study of oral GLP-1
The study, conducted in 16 healthy male subjects, was designed to explore the pharmacodynamic effects of a single oral dose of GLP-1 administered 15 minutes prior to an
The study, conducted in 16 healthy male subjects, was designed to explore the pharmacodynamic effects of a single oral dose of GLP-1 administered 15 minutes prior to an
Hemispherx is seeking marketing approval for the first-ever treatment for chronic fatigue syndrome (CFS). At present, only supportive, symptom-based care is available for CFS patients. The new drug
Franck Grimaud, CEO of Vivalis, said: “Vivalis is pleased to enter in this agreement to support Acambis’s R&D efforts for the development of new vaccines. “With already more
Bio-Bridge Science has one month to close the transaction, and obtain the new business license. The transaction is expected to close before the end of July 2008. Liang
This trial was designed to evaluate safety parameters for glycopyrrolate over a six-month period. Larry Dillaha, chief medical officer of Sciele Pharma, said: “We are excited to have
Heilongjiang Tianlong Pharmaceutical, a wholly-owned subsidiary of China Sky One Medical, has recently completed R&D for eight different types of injections, obtaining production approval for three injections, including
Bayer HealthCare’s Eovist is a paramagnetic MRI contrast agent that combines features of both an extracellular contrast agent and a hepatocyte-specific agent. The approval makes Eovist the first
Invitrogen’s Spot-Light Her2 CISH kit is based on a technology called chromogenic in situ hybridization (CISH). The test uses a DNA probe for the Her2 gene, which is
Following discussions and protocol agreement with the FDA, Samaritan will conduct an eight-week Phase II clinical study with SP-6310 in HIV-infected patients with abnormal cortisol levels while on
Dr Sabry has been a strategic advisor and member of the board of directors since March 2008. Dr Sabry succeeds Dinesh Patel in the position of president and